EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Endosialin-positive CAFs promote hepatocellular carcinoma progression by suppressing CD8 + T cell infiltration

Lunbiao Gan iD, Tong Lu iD, Yu Lu iD, Hongtao Song iD, Jiayu Zhang iD, Keying Zhang iD, Shiqi Lu iD, Xinjie Wu iD, Fengze Nie iD, Sijia Di iD, Donghui Han iD, Fa Yang iD und 2 weitere

Journal for ImmunoTherapy of Cancer · 2024-09 · 12 (9) · e009111

DOI: 10.1136/jitc-2024-009111 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 10.09.2024. Verfasst von Lunbiao Gan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Xi'an Key Laboratory of Stem Cell and Regenerative Medicine, Institute of Medical Research, Northwestern Polytechnical University, Xi'an, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, CD8-Positive T-Lymphocytes, Cancer-Associated Fibroblasts. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Innovation Capability Support Program of Shaanxi, National Natural Science Foundation of China, Natural Science Basic Research Program of Shaanxi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims Endosialin, also known as tumor endothelial marker1 or CD248, is a transmembrane glycoprotein that is mainly expressed in cancer-associated fibroblasts (CAFs) in hepatocellular carcinoma (HCC). Our previous study has found that endosialin-positive CAFs could recruit and induce the M2 polarization of macrophages in HCC. However, whether they may regulate other types of immune cells to promoting HCC progression is not known. Approach and results The growth of both subcutaneous and orthotopic HCC tumors was significantly inhibited in endosialin knockout (EN KO ) mice. Single-cell sequencing and flow cytometry analysis showed that tumor tissues from EN KO mice had increased CD8 + T cell infiltration. Mixed HCC tumor with Hepa1-6 cells and endosialin knockdown fibroblasts also showed inhibited growth and increased CD8 + T cell infiltration. Data from in vitro co-culture assay, chemokine array and antibody blocking assay, RNA-seq and validation experiments showed that endosialin inhibits the phosphorylation and nuclear translocation of STAT1 in CAFs. This inhibition leads to a decrease in CXCL9/10 expression and secretion, resulting in the suppression of CD8 + T cell infiltration. High level of endosialin protein expression was correlated with low CD8 + T infiltration in the tumor tissue of HCC patients. The combination therapy of endosialin antibody and PD-1 antibody showed synergistic antitumor effect compared with either antibody used individually. Conclusions Endosialin could inhibit CD8 + T cell infiltration by inhibiting the expression and secretion of CXCL9/10 in CAFs, thus promote HCC progression. Combination therapy with endosialin antibody could increase the antitumor effect of PD-1 antibody in HCC, which may overcome the resistance to PD-1 blockade.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsCD8-Positive T-LymphocytesCancer-Associated FibroblastsAnimalsMiceHumansAntigens, CDDisease ProgressionCell Line, TumorChemokine CXCL9Lymphocytes, Tumor-InfiltratingMice, KnockoutTumor MicroenvironmentSTAT1 Transcription FactorChemokine CXCL10MaleAntigens, NeoplasmNeoplasm Proteins

Stichwörter der Autor:innen

Combination therapyCytokineHepatocellular CarcinomaTumor infiltrating lymphocyte - TILTumor microenvironment - TME

Substanzen

CD248 protein, humanAntigens, CDChemokine CXCL9STAT1 Transcription FactorChemokine CXCL10CXCL9 protein, humantumor endothelial marker 1, mouseAntigens, NeoplasmNeoplasm Proteins

Autor:innen und Institutionen

  • Xi'an Key Laboratory of Stem Cell and Regenerative Medicine, Institute of Medical Research, Northwestern Polytechnical University, Xi'an, China.
  • Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
  • Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, China weihongwen@nwpu.edu.cn qinwj@fmmu.edu.cn yangfa0109@163.com.
  • Xi'an Key Laboratory of Stem Cell and Regenerative Medicine, Institute of Medical Research, Northwestern Polytechnical University, Xi'an, China weihongwen@nwpu.edu.cn qinwj@fmmu.edu.cn yangfa0109@163.com.

ORCID-Profile: Lunbiao Gan, Tong Lu, Yu Lu, Hongtao Song, Jiayu Zhang, Keying Zhang, Shiqi Lu, Xinjie Wu, Fengze Nie, Sijia Di, Donghui Han, Fa Yang, Weijun Qin, Weihong Wen

Förderung

  • Innovation Capability Support Program of Shaanxi
  • National Natural Science Foundation of China
  • Natural Science Basic Research Program of Shaanxi
  • the open project program of the State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for D…

Zitieren

APA

Gan, L., Lu, T., Lu, Y., Song, H., Zhang, J., Zhang, K., Lu, S., Wu, X., Nie, F., Di, S., Han, D., Yang, F., Qin, W., & Wen, W. (2024). Endosialin-positive CAFs promote hepatocellular carcinoma progression by suppressing CD8 + T cell infiltration. Journal for ImmunoTherapy of Cancer, 12(9), e009111. https://doi.org/10.1136/jitc-2024-009111

Vancouver

Gan L, Lu T, Lu Y, Song H, Zhang J, Zhang K, et al. Endosialin-positive CAFs promote hepatocellular carcinoma progression by suppressing CD8 + T cell infiltration. Journal for ImmunoTherapy of Cancer. 2024;12(9):e009111. doi:10.1136/jitc-2024-009111

BibTeX
@article{Gan2024,
  author = {Gan, Lunbiao and Lu, Tong and Lu, Yu and Song, Hongtao and Zhang, Jiayu and Zhang, Keying and Lu, Shiqi and Wu, Xinjie and Nie, Fengze and Di, Sijia and Han, Donghui and Yang, Fa and Qin, Weijun and Wen, Weihong},
  title = {Endosialin-positive CAFs promote hepatocellular carcinoma progression by suppressing CD8 + T cell infiltration},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  volume = {12},
  number = {9},
  pages = {e009111},
  doi = {10.1136/jitc-2024-009111}
}
Kostenlos starten →